Oral Intake Of Eranda Taila In The Management Of Primary Dysmenorrhea.

Randomized Controlled Clinical Trial Of Oral Administration Of Eranda Taila In The Management Of Udarvartini Yonivyapada With Special Reference To Primary Dysmenorrhea. - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/09/057578

Enrollment

Registered

2023-09-13

Start date

Unknown

Completion date

Unknown

Last updated

2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E308- Other disorders of puberty

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1 Painful Menstruation For Atleast 3 Consecutive Cycle 2 Patient With Regular Menstrual Cycle 21 to 35 days

Exclusion criteria

Exclusion criteria: 1 Patient Having Secondary Dysmenorrhea Like Fibroid Adenomyosis Endometriosis 2 Severe Anemic Hb less than 7 gm percent 3 Abdominal Pain Associated With Excessive Bleeding Per Vagina 4 Irregular Menstrual Cycle 5 Any Other Abdominal Pain Like Gastritis Colitis 6 Polycystic Ovarian Disease

Design outcomes

Primary

Measure	Time frame
To determine the efficacy of oral administration of eranda taila in the udavartini Yonivyapad With Special Reference Primary DysmenorrheaTimepoint: 4 week	—

Secondary

Measure	Time frame
To Compare The Efficacy Of Oral Administration Of Eranda Taila And Shatpushpa Churna In The Udavartini Yonivyapad With Special Reference To Primary DysmenorrheaTimepoint: Once in month for 3 months;To compare the efficacy of oral administration of eranda taila and shatpushpa churna in udavartini yonivyapad with special reference to primary dysmenorrheaTimepoint: 4 weeks	—

Countries

India

Contacts

Public ContactDr Dilip Vitthal Katare

Hon Shri Annasaheb Dange Ayurved Medical College Post Graduate and Research Centre Ashta

drdilipkatareashta@gmail.com9881215521

Outcome results